This site is intended for Healthcare Professionals only.

EU disease prevention agency sees risk of Covid deaths rising as Omicron subvariants spread


Share post:

Two new subvariants of Omicron — BA.4 and BA.5 — are spreading much faster than other corovanirus variants in Europe, which could lead to more hospitalizations and deaths as they become dominant, the EU’s disease prevention agency said on Monday (June 13).

Most EU countries have so far detected low rates of the two subgroups. But in countries where the proportion has risen – such as Portugal, where BA.5 accounted for 87 per cent of cases by May 30 — there have been surges in overall cases, according to the European Centre for Disease Prevention and Control (ECDC).

The two sublineages were added to the World Health Organization’s monitoring list in March and have also been designated as variants of concern by the ECDC.

Variants BA.4 and BA.5 do not appear to carry a higher risk of severe disease than other forms of Omicron. But an increase in case numbers from higher transmission rates risks leading to an increase in hospitalizations and deaths, the agency said.

“The growth advantage reported for BA.4 and BA.5 suggest that these variants will become dominant,” ECDC said in a statement on its website.

Meanwhile, its US counterpart said last week BA.4 and BA.5 were estimated to make up nearly 5 per cent and 8 per cent, respectively, of coronavirus cases as of June 4.


Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

ABPI: Increased pharma exports could boost GDP by £16.3 billion

ABPI urges political leaders to enhance healthcare and economic growth through strategic partnership The Association of the British Pharmaceutical...

The Importance Of Expanding Access To Dental Care For Rural And Undeserved Populations

In many rural areas and underserved neighborhoods, a critical issue is quietly emerging. Although often overlooked, its effects...

BGMA: More than 50% of UK generics face shortages without licensed alternatives

Brexit blamed by BGMA CE, Mark Samuels, as UK faces critical shortages in generic drug supply A recent report...

Paul Burden elected BGMA Vice-Chair, bringing 25 years of industry leadership

Veteran of off-patent sector to drive strategic engagement and patient access initiatives at BGMA The British Generic Manufacturers Association...